lanreotide + non-steroidal antiandrogens + luteinizing hormone-releasing hormone agonist

This is a **combination regimen** consisting of three pharmacological agents: **lanreotide** (a somatostatin analog), a **non-steroidal antiandrogen** (e.g., bicalutamide, flutamide, nilutamide), and a **luteinizing hormone-releasing hormone (LHRH) agonist** (e.g., goserelin, leuprolide, triptorelin). This combination is used primarily for advanced hormone-dependent cancers (notably prostate cancer and, less commonly, certain neuroendocrine tumors), leveraging synergistic endocrine and antiproliferative effects. - **Lanreotide** acts by binding somatostatin receptors (mainly SSTR2, also SSTR5) to suppress hormone secretion and cell proliferation, particularly in neuroendocrine tumors[5][3]. - **Non-steroidal antiandrogens** competitively inhibit androgen binding to the androgen receptor, blocking testosterone-mediated signaling in prostate tissue and tumors. - **LHRH agonists** initially stimulate pituitary LH and FSH release, causing a transient testosterone surge, then downregulate the pituitary-gonadal axis, leading to suppressed testosterone (medical castration)[6][2]. This combination is most characteristic of androgen deprivation therapy intensification in prostate cancer and may be considered experimentally in certain hormone-driven neuroendocrine tumors.